| Date | Partners | Compound / Disease area / Development phase | Type of agreement | Nature / Financial terms |
|---|---|---|---|---|
| 2010-08-24 | Kamada Ltd (Israel) Baxter (USA) |
Glassia® (human Alpha 1-Proteinase Inhibitor) / emphysema due to congenital deficiency of alpha 1-proteinase inhibitor (Alpha 1-PI), also known as alpha 1-antitrypsin (AAT) deficiency |
commercialization/ distribution |
See details |
| 2010-08-24 | Aileron Therapeutics (USA) Roche (Switzerland) |
stapled peptide therapeutics This new kind of peptides is the result of Aileron’s peptide stabilization technology. Aileron’s proprietary technology platform “locks” peptides into their biologically active shape, mimicking the structures found in nature. This process captures the best features of both small molecules and therapeutic proteins, ultimately endowing the peptide with unique and beneficial drug-like properties, including efficient cell penetration, improved pharmacokinetics, high-affinity binding to large target protein surfaces and excellent stability within the body. This could expand the number of "druggable" therapeutic targets, by providing an opportunity to address the thousands of intracellular protein-protein interactions that remain a challenge for functional modulation by current therapeutics. / oncology, virology, inflammation, metabolism and CNS |
R&D commercialization/ distribution development |
See details |
| 2010-08-18 | CEVEC Pharmaceuticals (Germany) Life Technologies Corporation (USA) |
Human CAP-T® Technology The CAP-T protein production technology is based on CAP cells, a human immortalized cell line for stable protein production derived from amniocytes. CAP cells are optimized to growth in serum-free suspension cultures and show human-like post-translational modifications including authentic human glycosylation patterns. |
licensing |
See details |
| 2010-08-11 | PregLem (Switzerland) Merck Serono (Germany- Switzerland) |
Bentamapimod (orally active Jun Kinase Inhibitor, JNK-I AS602801) / prevention of post-surgical abdominal adhesions and endometriosis in patients with tubal ligation or comparable effective contraception |
licensing |
See details |
| 2010-08-10 | NsGene (Denmark) Biogen Idec (USA) |
Neublastin (disease-modifying therapeutic protein) / neuropathic pain | licensing commercialization/ distribution development |
See details |
| 2010-08-05 | Lonza (Switzerland) Roslin Cells Ltd (UK) |
Customized cell culture media and processes for the production of pluripotent stem cells in the field of cell therapy |
R&D development |
See details |
| 2010-08-04 | Proximagen (UK) BrainCells (USA) |
Sabcomeline (muscarinic partial agonist) / Psychiatric and neurologic disorders |
other |
See details |
| 2010-08-03 | Telormedix (Switzerland) Swiss Tropical and Public Health Institute (Swiss TPH - Switzerland) |
TMX-201 This second generation TLR7 molecule is intended to act as an activator of the innate immune system and enhance the process of immunisation. / Malaria and Buruli Ulcer |
R&D other |
See details |
| 2010-07-29 | SynCo Bio Partners (The Netherlands) Versatis (USA) |
VRS-317 (once monthly form of human growth hormone) / growth hormone deficiency |
manufacturing |
See details |
| 2010-07-27 | Protaffin (Austria) CMC Biologics (Denmark/USA) |
PA401 (glycan-binding decoy protein based on human chemokine IL-8 - CXCL8) A composition of matter patent covering PA401 has been granted in the USA and the EU. / chronic obstructive pulmonary disease (COPD) |
manufacturing |
See details |
| 2010-07-26 | NovImmune (Switzerland) Genentech (USA) |
anti-IL17 fully human monoclonal antibody and back-up antibodies | licensing |
See details |
| 2010-07-22 | Algeta (Norway) Institute for Energy Technology (Norway) |
Alpharadin® (radium-223 chloride) / cancer | manufacturing |
See details |
| 2010-07-22 | Algeta (Norway) Bayer Schering Pharma (Germany) |
Alpharadin® (radium-223 chloride) / cancer | manufacturing commercialization/ distribution |
See details |
| 2010-07-20 | Selvita (Poland) Rottapharm Madaus (Italy) |
Drug discovery services | R&D other |
See details |
| 2010-07-19 | MediGene (Germany) Astellas Pharma (Japan) |
Eligard® (leuprolide acetate) / hormone-dependent prostate cancer |
licensing other |
See details |
